OBJECTIVE: To identify the effects of GnRH agonist therapy on body composition (lean and fat mass components) and body fat distribution. METHODS: Fifteen women with uterine leiomyomas were given a GnRH agonist (leuprorelin acetate, 3.75 mg) monthly for 4 months. Weight, height, and body mass index (BMI, weight/height) were recorded. Regional and total body composition, trunk-leg fat ratio, bone mineral density of the lumbar spine (L2-L4), and total body were assessed by whole-body scanning with dual-energy x-ray absorptiometry before and after treatment. Uterine volume was measured by transabdominal ultrasonography. RESULTS: The mean (+/- standard deviation [SD]) lean mass of total body, trunk, and leg decreased significantly (36.3 +/- 4.9 to 35.4 +/- 4.4 kg, P <.01; 18.8 +/- 2.8 to 18.1 +/- 2.8 kg, P <.05; and 11.4 +/- 1.8 to 11.1 +/- 1.6 kg, P <.05; respectively), whereas body fat mass, percentage of body fat, and trunk fat mass increased significantly (20.8 +/- 4.8 to 21.8 +/- 4.6 kg, P <.01; 34.9 +/- 5.9 to 36.5 +/- 5.2%, P <.01; and 8.6 +/- 3.0 to 9.3 +/- 3.0 kg, P <.01; respectively). Trunk-leg fat ratio increased significantly (1.03 +/- 0.32 to 1.12 +/- 0.33, P <.05). Weight, BMI, arm tissue composition (lean and fat mass components), and leg fat mass did not change during 4 months of GnRH agonist therapy. Bone mineral density and uterine volume decreased significantly. CONCLUSION: Hypogonadism by GnRH agonist therapy induces lean mass loss, increased adiposity overall, and upper body fat accumulation.
OBJECTIVE: To identify the effects of GnRH agonist therapy on body composition (lean and fat mass components) and body fat distribution. METHODS: Fifteen women with uterine leiomyomas were given a GnRH agonist (leuprorelin acetate, 3.75 mg) monthly for 4 months. Weight, height, and body mass index (BMI, weight/height) were recorded. Regional and total body composition, trunk-leg fat ratio, bone mineral density of the lumbar spine (L2-L4), and total body were assessed by whole-body scanning with dual-energy x-ray absorptiometry before and after treatment. Uterine volume was measured by transabdominal ultrasonography. RESULTS: The mean (+/- standard deviation [SD]) lean mass of total body, trunk, and leg decreased significantly (36.3 +/- 4.9 to 35.4 +/- 4.4 kg, P <.01; 18.8 +/- 2.8 to 18.1 +/- 2.8 kg, P <.05; and 11.4 +/- 1.8 to 11.1 +/- 1.6 kg, P <.05; respectively), whereas body fat mass, percentage of body fat, and trunk fat mass increased significantly (20.8 +/- 4.8 to 21.8 +/- 4.6 kg, P <.01; 34.9 +/- 5.9 to 36.5 +/- 5.2%, P <.01; and 8.6 +/- 3.0 to 9.3 +/- 3.0 kg, P <.01; respectively). Trunk-leg fat ratio increased significantly (1.03 +/- 0.32 to 1.12 +/- 0.33, P <.05). Weight, BMI, arm tissue composition (lean and fat mass components), and leg fat mass did not change during 4 months of GnRH agonist therapy. Bone mineral density and uterine volume decreased significantly. CONCLUSION: Hypogonadism by GnRH agonist therapy induces lean mass loss, increased adiposity overall, and upper body fat accumulation.
Authors: Edward L Melanson; Kathleen M Gavin; Karen L Shea; Pamela Wolfe; Margaret E Wierman; Robert S Schwartz; Wendy M Kohrt Journal: J Appl Physiol (1985) Date: 2015-09-03
Authors: Rachael E Van Pelt; Wendolyn S Gozansky; Robert C Hickner; Robert S Schwartz; Wendy M Kohrt Journal: Obesity (Silver Spring) Date: 2006-12 Impact factor: 5.002
Authors: Karen L Shea; Kathleen M Gavin; Edward L Melanson; Ellie Gibbons; Anne Stavros; Pamela Wolfe; John M Kittelson; Sheryl F Vondracek; Robert S Schwartz; Margaret E Wierman; Wendy M Kohrt Journal: Menopause Date: 2015-10 Impact factor: 2.953
Authors: Carlos Olvera-Sandoval; Gabriel Betanzos-Cabrera; Rafael Casillas-Peñuelas; J Luis Quintanar Journal: Exp Ther Med Date: 2017-10-23 Impact factor: 2.447
Authors: Edward L Melanson; Kate Lyden; Ellie Gibbons; Kathleen M Gavin; Pamela Wolfe; Margaret E Wierman; Robert S Schwartz; Wendy M Kohrt Journal: Med Sci Sports Exerc Date: 2018-08 Impact factor: 5.411
Authors: Kathleen M Gavin; Edward L Melanson; Kerry L Hildreth; Ellie Gibbons; Daniel H Bessesen; Wendy M Kohrt Journal: Obesity (Silver Spring) Date: 2020-11 Impact factor: 5.002
Authors: Young-Min Park; Catherine M Jankowski; Cemal Ozemek; Kerry L Hildreth; Wendy M Kohrt; Kerrie L Moreau Journal: J Appl Physiol (1985) Date: 2020-04-16